205 related articles for article (PubMed ID: 23291944)
1. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
[TBL] [Abstract][Full Text] [Related]
2. Adverse events following yellow fever vaccination in immunocompromised persons.
Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
[TBL] [Abstract][Full Text] [Related]
3. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
4. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
5. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
6. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
7. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?
Thomas RE; Spragins W; Lorenzetti DL
Vaccine; 2013 Dec; 31(52):6201-9. PubMed ID: 24436960
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
10. Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011.
Jentes ES; Han P; Gershman MD; Rao SR; LaRocque RC; Staples JE; Ryan ET; The Global TravEpiNet Consortium
Am J Trop Med Hyg; 2013 May; 88(5):954-961. PubMed ID: 23458961
[TBL] [Abstract][Full Text] [Related]
11. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
12. Yellow fever vaccination status and safety in hemodialysis patients.
Facincani T; Guimarães MN; De Sousa Dos Santos S
Int J Infect Dis; 2016 Jul; 48():91-5. PubMed ID: 27208638
[TBL] [Abstract][Full Text] [Related]
13. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
14. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
15. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
[TBL] [Abstract][Full Text] [Related]
16. Yellow fever vaccination: how much is enough?
Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
[TBL] [Abstract][Full Text] [Related]
17. Yellow fever vaccine: an effective vaccine for travelers.
Verma R; Khanna P; Chawla S
Hum Vaccin Immunother; 2014; 10(1):126-8. PubMed ID: 24056028
[TBL] [Abstract][Full Text] [Related]
18. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
[TBL] [Abstract][Full Text] [Related]
19. Suspected YF-AND after yellow fever vaccination in Finland.
Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
[TBL] [Abstract][Full Text] [Related]
20. Yellow fever vaccine for patients with HIV infection.
Barte H; Horvath TH; Rutherford GW
Cochrane Database Syst Rev; 2014 Jan; (1):CD010929. PubMed ID: 24453061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
